Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals Inc. emerged with a resolute focus, aiming to transform the landscape for individuals grappling with rare genetic disorders of obesity. Founded on the premise that certain predispositions to obesity are deeply rooted in genetics, Rhythm embarked on a journey to develop treatments that target the melanocortin-4 receptor (MC4R) pathway. This pathway plays a critical role in regulating hunger, energy expenditure, and overall body weight. Their flagship product, Imcivree (setmelanotide), gained approval and marked a significant stride forward for the company. It is specifically designed to address the underlying genetic causes of obesity, offering hope to patients who previously had limited therapeutic options.
The business model of Rhythm Pharmaceuticals is patient-centric, grounded in innovation and strategic collaborations. They generate revenue through the commercialization of Imcivree, facilitated by partnerships with healthcare providers and institutions that benefit from the specialized treatment they offer. Additionally, Rhythm actively invests in research and development, continually seeking to expand the applicability of their products to other genetic obesity-related conditions. By maintaining a robust pipeline and leveraging scientific advancements, the company positions itself as a pioneer in addressing an underserved niche, sustainably growing through targeted drug development and market expansion initiatives.
Rhythm Pharmaceuticals Inc. emerged with a resolute focus, aiming to transform the landscape for individuals grappling with rare genetic disorders of obesity. Founded on the premise that certain predispositions to obesity are deeply rooted in genetics, Rhythm embarked on a journey to develop treatments that target the melanocortin-4 receptor (MC4R) pathway. This pathway plays a critical role in regulating hunger, energy expenditure, and overall body weight. Their flagship product, Imcivree (setmelanotide), gained approval and marked a significant stride forward for the company. It is specifically designed to address the underlying genetic causes of obesity, offering hope to patients who previously had limited therapeutic options.
The business model of Rhythm Pharmaceuticals is patient-centric, grounded in innovation and strategic collaborations. They generate revenue through the commercialization of Imcivree, facilitated by partnerships with healthcare providers and institutions that benefit from the specialized treatment they offer. Additionally, Rhythm actively invests in research and development, continually seeking to expand the applicability of their products to other genetic obesity-related conditions. By maintaining a robust pipeline and leveraging scientific advancements, the company positions itself as a pioneer in addressing an underserved niche, sustainably growing through targeted drug development and market expansion initiatives.
Revenue Growth: Rhythm's Q4 2025 revenue was $57.3 million, up 12% quarter-over-quarter and 37% year-over-year; full-year 2025 revenue reached $194.8 million, up about 50% from 2024.
US vs ex-US Sales: 68% of Q4 revenue came from the US, with international sales rising to 32% of product revenue.
Bivamelagon Progress: Positive Phase 2 results for Bivamelagon in HO with up to 14.3% mean BMI reduction at 600mg; Phase 3 expected to start by year-end 2026.
IMCIVREE Launch Preparation: Teams are readying for the acquired hypothalamic obesity (HO) launch, pending a PDUFA decision by March 20, 2026.
Japan & Europe Expansion: Rhythm is building out operations in Japan (estimated 5,000–8,000 patients) and expects top-line Japanese data in March, with European EMA review ongoing.
Operating Expenses: 2026 non-GAAP operating expenses are guided to $385–415 million, up about 35% from 2025, driven by clinical and commercial investments.
Cash Position: The company ended 2025 with $389 million in cash, expected to fund operations for at least 24 months.
Inventory Impact: Increased specialty pharmacy inventory in Q4 2025 may dampen Q1 2026 sales, a pattern also seen last year.
